Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chrysalis jumps after keeping stake in Klarna post-IPO

(Sharecast News) - Shares in Chrysalis Investments jumped as the trust retained its stake in Swedish payments firm Klarna, which launched its US IPO on Wednesday.

The company revealed it had retained its 4.2 million share stake in Klarna - which raised more than $1bn, as its long-awaited US initial public offering got underway.

"The investment adviser believes Klarna is well-positioned to benefit from attractive growth prospects over the medium-term. In line with other major Klarna shareholders, the company's shareholding in Klarna is subject to a customary lock-up period of six months from IPO," the company said.

The Swedish fintech, which opted to listed in New York, is understood to have sold 34.3m shares at $40 per share, above the targeted range of between $35 and $37.

The sale is understood to have raised a total of $1.37bn and valued Klarna at just over $15bn. Chrysalis said its assessed market valuation of Klarna as at 30 June 2025 was approximately $16.6bn, valuing its stake at £137m.

It first invested in Klarna in August 2019 at a valuation of $5.5bn. Chrysalis said its blended entry price across three rounds of investment was aroun $25.60 a share, representing a money multiple of approximately 1.6x (unrealised) at Klarna's IPO valuation.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.